Compare AWI & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AWI | PTGX |
|---|---|---|
| Founded | 1860 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Plastic Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 6.4B |
| IPO Year | 1994 | 2016 |
| Metric | AWI | PTGX |
|---|---|---|
| Price | $154.96 | $97.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | ★ $207.50 | $108.23 |
| AVG Volume (30 Days) | 342.4K | ★ 462.9K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.80% | N/A |
| EPS Growth | ★ 17.61 | N/A |
| EPS | ★ 1.55 | 0.05 |
| Revenue | ★ $1,620,800,000.00 | N/A |
| Revenue This Year | $10.32 | $874.25 |
| Revenue Next Year | $6.71 | N/A |
| P/E Ratio | ★ $98.55 | $2,055.80 |
| Revenue Growth | ★ 12.11 | N/A |
| 52 Week Low | $149.07 | $49.86 |
| 52 Week High | $206.08 | $107.84 |
| Indicator | AWI | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 38.19 | 47.17 |
| Support Level | $151.98 | $96.36 |
| Resistance Level | $162.98 | $104.85 |
| Average True Range (ATR) | 4.00 | 4.25 |
| MACD | -0.03 | -0.26 |
| Stochastic Oscillator | 29.85 | 42.59 |
Armstrong World Industries Inc designs and manufactures exterior architectural applications, including ceilings, specialty walls, and exterior metal solutions, using materials such as mineral fiber, fiberglass, metal, felt, architectural resin and glass, wood, wood fiber, and glass-reinforced-gypsum. Its segments include Mineral Fiber, which produces suspended mineral fiber and fiberglass ceiling systems and includes results from the Worthington Armstrong Venture (WAVE) for ceiling suspension system (grid) products; Architectural Specialties, which designs, produces, and sources specialty ceilings, walls, and other architectural applications for commercial settings, with revenues mainly project driven; and Unallocated Corporate. The company operates in the United States and Canada.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.